Name: Antibody |
Target: Antibody Type |
Indication | Company | Approval Date |
*OKT3: Muronomab-CD3 |
CD3: Murine, IgG2a |
Autoimmune | Johnson & Johnson | 1986 (US) |
ReoPro: Abciximab |
PIIb/IIIa: Chimeric, IgG1, Fab |
Homeostasis | Johnson & Johnson | 1984 (US) |
Rituxan: Rituximab |
CD20: Chimeric, IgG1 |
Cancer | Genentech | 1997 (US) |
1998 (EU) | ||||
*Zenapax: Daclizumab |
CD25: Humanized, IgG1 |
Autoimmune | Roche | 1997 (US) |
1999 (EU) | ||||
Simulect: Basiliximab |
CD25: Chimeric, IgG1 |
Autoimmune | Novartis | 1998 (US) |
1998 (EU) | ||||
Synagis: Palivizumab |
RSV: Humanized, IgG1 |
Infections | MedImmune | 1998 (US) |
1999 (EU) | ||||
Remicade: Infliximab |
TNFa: Chimeric, IgG1 |
Autoimmune | Johnson & Johnson | 1998 (US) |
1999 (EU) | ||||
Herceptin: Trastuzumab |
HER2: Humanized, IgG1 |
Cancer |
Genentech/ Roche |
1998 (US) |
2000 (EU) | ||||
*Mylotarg: Gemtuzumab ozogamicin |
CD33: Humanized, IgG4, immunotoxin |
Cancer |
Wyeth/ Pfizer |
2000 (US) |
Campath: Alemtuzumab |
CD52: Humanized, IgG1 |
Cancer | Genzyme | 2001 (US) |
2001 (EU) | ||||
Zevalin: Ibritumomab tiuxetan |
CD20: Murine, IgG1, radiolabeled (Yttrium 90) |
Cancer | Biogen Idec | 2002 (US) |
2004 (EU) | ||||
Humira: Adalimumab |
TNFa: Human, IgG1 |
Autoimmune | Abbott | 2002 (US) |
2003 (EU) | ||||
Xolair: Omalizumab |
IgE: Humanized, IgG1 |
Autoimmune |
Genentech/ Roche |
2003 (US) |
Bexxar: Tositumomab-I-131 |
CD20: Murine, IgG2a, radiolabeled (Iodine 131) |
Cancer | Corixa/GSK | 2003 (US) |
*Raptiva: Efalizumab |
CD11a: Humanized, IgG1 |
Autoimmune |
Genentech/ Roche |
2003 (US) |
2004 (EU) | ||||
Erbitux: Cetuximab |
EGFR: Chimeric, IgG1 |
Cancer |
Imclone/ Lilly |
2004 (US) |
2004 (EU) | ||||
Avastin: Bevacizumab |
VEGF: Humanized, IgG1 |
Cancer |
Genentech/ Roche |
2004 (US) |
2005 (EU) | ||||
Tysabri: Natalizumab |
a4-Intergrin: Humanized, IgG4 |
Autoimmune | Biogen Idec | 2004 (US) |
Actemra: Tocilizumab |
Anti-IL-6R: Humanized, IgG1 |
Autoimmune |
Chugai/ Roche |
2005 (JP) 2010 (US) |
Vectibix: Panitumumab |
EGFR: Human, IgG2 |
Cancer | Amgen | 2006 (US) |
Lucentis: Ranibizumab | VEGF: Humanized IgG1 Fab | Macular degeneration |
Genentech/ Roche |
2006 (US) |
Soliris: Eculizumab |
C5: Humanized IgG2/4 |
Blood disorders | Alexion | 2007 (US) |
Cimzia: Certolizumab pegol |
TNFa: Humanized, pegylated Fab |
Autoimmune | UCB | 2008 (US) |
Simponi: Golimumab |
TNFa: Human IgG1 | Autoimmune | Johnson & Johnson | 2009 (US, EU, CAN) |
Ilaris: Canakinumab |
IL1b: Human IgG1 |
Infalmmatory | Novartis | 2009 (US,EU) |
Stelara: Ustekinumab |
IL-12/23: Human IgG1 | Autoimmune | Johnson & Johnson | 2009 (US) |
2008 (EU) |
||||
Arzerra: Ofatumumab |
CD20: Human IgG1 | Cancer | Genmab | 2009 (EU) |
Prolia: Denosumab |
RANK ligand: Human IgG2 | Bone Loss | Amgen | 2010 (US) |
Numax: Motavizumab |
RSV: Humanized IgG1 | Anti-infective | Meddimmune | Pending |
ABThrax: Raxibacumab |
B. anthrasis PA: Human IgG1 |
Anti-infection | GSK | 2012 (US) |
Benlysta: Belimumab |
BLyS: Human IgG1 | Autoimmune | Human Genome Sciences | 2011 (US) |
Yervoy: Ipilimumab |
CTLA-4: Human IgG1 | Cancer | BMS | 2011 (US) |
Adcetris: Brentuximab Vedotin |
CD30: Chimeric, IgG1, Drug-conjugate | Cancer | Seattle Genetics | 2011 (US) |
Perjeta: Pertuzumab |
Her2: Humanized, IgG1 | Cancer | Genentech/ Roche |
2012 (US) |
Kadcyla: Ado-trastuzumab emtansine |
Her2: Humanized, IgG1, Drug-conjugate | Cancer | Genentech/ Roche |
2013 (US) |
Gazyva: Obinutuzumab |
CD20:
humanized and glyco-engineered |
Cancer | Genentech/ Roche |
2013 (US) |